Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Cash & Equivalents (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Cash & Equivalents for 11 consecutive years, with $1.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash & Equivalents fell 84.8% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Jun 2025, down 84.8%, and an annual FY2024 reading of $3.8 million, up 54.23% over the prior year.
  • Cash & Equivalents was $1.0 million for Q2 2025 at Kiora Pharmaceuticals, down from $3.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $31.3 million in Q1 2024 and bottomed at $1.0 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $6.8 million, with a median of $5.3 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents surged 811.9% in 2024, then tumbled 84.8% in 2025.
  • Year by year, Cash & Equivalents stood at $7.9 million in 2021, then crashed by 38.6% to $4.9 million in 2022, then plummeted by 49.31% to $2.5 million in 2023, then surged by 54.23% to $3.8 million in 2024, then plummeted by 73.63% to $1.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for KPRX at $1.0 million in Q2 2025, $3.8 million in Q4 2024, and $5.6 million in Q3 2024.